Hormonal contraception and chemoprevention of female cancers

Endocrine-Related Cancer

Volumn 7, Issue 2, 2000, Pages 73-83

  Pike, M C ^a   Spicer, D V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ETHINYLESTRADIOL; GONADORELIN AGONIST; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; OVARY CANCER; REVIEW; UTERINE CERVIX CANCER;

EID: 0033863360     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0070073     Document Type: Review

References (58)

1. Anderson TJ, Battersby S, King RJB, McPherson K & Going JJ 1989 Oral contraceptive use influences resting breast proliferation. Human Pathology 20 1139-1144.
2. Baum M 1999 Adjuvant treatment of premenopausal breast cancer with zoladex and tamoxifen: results from the ZIPP trial organized by the Cancer Research Campaign (CRC) Breast Cancer Trials Group. Breast Cancer Research and Treatment 57 30 (Abstract).
3. Bernstein L, Yuan JM, Ross RK, Pike MC, Lobo RA, Stanczyk F, Gao YT & Henderson BE 1990 Serum hormone levels in premenopausal Chinese women in Shanghai and white women in Los Angeles. Cancer Causes and Control 1 51-58.
4. Brinton LA, Huggins GR, Lehman HF, Mallin K, Savitz DA, Trapido E, Rosenthal J & Hoover R 1986 Long-term use of oral contraceptives and risk of invasive cervical cancer. International Journal of Cancer 38 339-344.
5. Casagrande JT, Louie EW, Pike MC, Ross RK, Louie EW, Roy S & Henderson BE 1979 'Incessant ovulation' and ovarian cancer. Lancet ii 170-173.
6. Centers for Disease Control 1983a Oral contraceptive use and the risk of ovarian cancer. Journal of the American Medical Association 249 1596-1599.
7. Centers for Disease Control 1983b Oral contraceptive use and the risk of endometrial cancer. Journal of the American Medical Association 249 1600-1604.
8. Centers for Disease Control 1987a The reduction in risk of ovarian cancer associated with oral contraceptive use. New England Journal of Medicine 316 650-655.
9. Centers for Disease Control 1987b Combination oral contraceptive use and the risk of endometrial cancer. Journal of the American Medical Association 257 796-800.
10. Cerin A, Heldaas K & Moeller B 1996 Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy. New England Journal of Medicine 334 668-669.
11. Cook GA & Draper GJ 1984 Trends in cervical cancer and carcinoma in situ in Great Britain. British Journal of Cancer 50 367-375.
12. Cutler SJ & Young JL 1975 Third National Cancer Survey: Incidence Data. National Cancer Institute Monograph 41.
13. Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM & Hendrickson MR 1994 Cyclic hormone replacement therapy using quarterly progestin. Obstetrics and Gynecology 83 693-700.
14. Fanchin R, de Ziegler D, Bergeron C, Righini C, Torrisi C & Frydman R 1997 Transvaginal administration of progesterone. Obstetrics and Gynecology 90 396-401.
15. Fathalla MF 1971 Incessant ovulation - a factor in ovarian neoplasia? Lancet ii 163.
16. Fathalla MF 1972 Factors in the causation and incidence of ovarian cancer. Obstetrical and Gynecological Survey 27 751-758.
17. Feig SA 1994 Hormonal reduction of mammographic densities: potential effects on breast cancer risk and performance of diagnostic and screening mammography. Journal of the National Cancer Institute 86 408-409.
18. Ferenczy A, Bertrand G & Gelfand MM 1979 Proliferation kinetics of human endometrium during the normal menstrual cycle. American Journal of Obstetrics and Gynecology 133 859-867.
19. Flowers CE, Wilborn WH & Hyde BM 1983 Mechanisms of uterine bleeding postmenopausal patients receiving estrogen alone or with a progestin. Obstetrics and Gynecology 61 135-143.
20. Goebelsmann U & Mishell DR 1979 The menstrual cycle. In Reproductive Endocrinology, Infertility and Contraception, pp 67-89. Eds DR Mishell & V Davajan. Philadelphia: FA Davis Company.
21. Goldin BR, Adlercreutz H, Gorbach SL, Woods MN, Dwyer JT, Conlon T, Bohn E & Gershoff SN 1986 The relationship between estrogen levels and diets of Caucasian American and Oriental immigrant women. American Journal of Clinical Nutrition 44 945-953.
22. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T & Barrett-Connor E 1999 Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Annals of Internal Medicine 130 262-269.
23. Grove RD, Hetzel AM & National Center for Health Statistics (US) 1968 Vital Statistics Rates in the United States 1940-1960, Table 17.1-ix, 881. US National Center for Health Statistics; Superintendent of Documents, US Government Printing Office, Washington DC.
24. Henderson BE, Casagrande JT, Pike MC, Mack TM, Rosario I & Duke A 1983 The epidemiology of endometrial cancer in young women. British Journal of Cancer 47 749-756.
25. Hoel DG, Wakabayashi T & Pike MC 1983 Secular trends in the distributions of the breast cancer risk factors - menarche, first birth, menopause, and weight - in Hiroshima and Nagasaki, Japan. American Journal of Epidemiology 118 78-89.
26. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA & Haslam SZ 1999 Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. Journal of Clinical Endocrinology and Metabolism 84 4559-4565.
27. Irwin KL, Rosero-Bixby L, Oberle MW, Lee NC, Whatley AS, Fortnery JA & Bonhomme MG 1988 Oral contraceptives and cervical cancer risk in Costa Rica. Journal of the American Medical Association 259 59-64.
28. Japan Statistical Yearbook 1998 Table 2-25. Statistics Bureau of the Management and Coordination Agency, Government of Japan 1997.
29. Key TJA & Pike MC 1988a The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. British Journal of Cancer 57 205-212.
30. Key TJA & Pike MC 1988b The role of estrogens and progestogens in the epidemiology and prevention of breast cancer. European Journal of Cancer and Clinical Oncology 24 29-43.
31. Key TJA, Chen J, Wang DY, Pike MC & Boreham J 1990 Sex hormones in women in rural China and in Britain. British Journal of Cancer 62 631-636.
32. King RJB & Whitehead MI 1984 Progestin action in relation to the prevention of endometrial abnormalities. In Medical Management of Endometriosis, pp 67-77. Eds J-P Raynaud, T Ojasoo & L Martini. New York: Raven Press.
33. Konishi I, Fujii S, Nonogaki H, Nanbu Y, Iwai T & Mori T 1991 Immunohistochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papillomavirus DNA in normal and neoplastic epithelium of the uterine cervix. Cancer 68 1340-1350.
34. Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJB & Whitehead MI 1986 Is Provera the ideal progesterone for addition to postmenopausal estrogen therapy? Fertility and Sterility 45 345-352.
35. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami H-O & Persson I 1999 Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. International Journal of Cancer 81 339-344.
36. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L & Sauer MV 1994 Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertility and Sterility 62 485-490.
37. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet J-S & Ponder BJ 1998 Oral contraceptives and the risk of hereditary ovarian cancer. New England Journal of Medicine 339 424-428.
38. Paterson MEL, Wade-Evans T, Sturdee DW, Thom MH & Studd JWW 1980 Endometrial disease after treatment with oestrogens and progestogens in the climacteric. British Medical Journal 22 822-824.
39. Peters RK, Thomas D, Hagan DG, Mack TM & Henderson BE 1986 Risk factors for invasive cervical cancer among Latinas and Non-Latinas in Los Angeles County. Journal of the National Cancer Institute 77 1063-1077.
40. Pike MC 1987 Age-related factors in cancers of the breast, ovary and endometrium. Journal of Chronic Diseases 40 59-69.
41. Pike MC & Spicer DV 1993 Oral contraceptives and cancer. In Contraception, pp 67-84. Eds D Shoupe & F Haseltine. New York: Springer-Verlag.
42. Pike MC, Ross RK, Lobo RA, Key TJA, Potts M & Henderson BE 1989 LHRH agonists and the prevention of breast and ovarian cancer. British Journal of Cancer 60 142-148.
43. Pike MC, Spicer DV, Dahmoush L & Press MF 1993 Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiologic Reviews 15 17-35.
44. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC & Mack TM 1997 Estrogen-progestin replacement therapy and endometrial cancer. Journal of the National Cancer Institute 89 1110-1116.
45. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber J, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT & Weber BL 1999 Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. Journal of the National Cancer Institute 91 1475-1479.
46. Risch HA, Weiss NS, Lyon JL, Daling JR & Liff JM 1983 Events of reproductive life and the incidence of epithelial ovarian cancer. American Journal of Epidemiology 177 128-139.
47. Ross RK, Paganini-Hill A, Wan PC & Pike MC 2000 Estrogen versus estrogen-progestin hormone replacement therapy: effect on breast cancer risk. Journal of the National Cancer Institute 92 328-332.
48. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L & Hoover R 2000 Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. Journal of the American Medical Association 283 485-491.
49. Schiff I, Sela HK, Cramer D, Tulchinskiy D & Ryan KJ 1982 Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertility and Sterility 37 79-82.
50. Shoupe D, Meme D, Mezrow G & Lobo RA 1991 Prevention of endometrial hyperplasia in postmenopausal women with intrauterine progesterone. New England Journal of Medicine 325 1811-1812.
51. Spicer D, Shoupe D & Pike MC 1991 GnRH agonists as contraceptive agents: predicted significantly reduced risk of breast cancer. Contraception 44 289-310.
52. Spicer DV, Pike MC, Pike A, Rude R, Shoupe D & Richardson J 1993 Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception 47 427-444.
53. Spicer D, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A & Pike MC 1994 Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. Journal of the National Cancer Institute 86 431-436.
54. Waterhouse J, Muir C, Correa P & Powell J (eds) 1976 Cancer Incidence in Five Continents, vol 3. Scientific Publication No. 15. Lyon: International Agency for Cancer Research.
55. Weiderpass E, Hans-Olov A, Baron JA, Magnusson C, Bergstrom R, Lindgren A, Correia N & Persson I 1999 Risk of endometrial cancer following estrogen replacement with and without progestins. Journal of the National Cancer Institute 91 1131-1137.
56. Willett WC, Bain C, Hennekens CH, Rosner B & Speizer FE 1981 Oral contraceptives and risk of ovarian cancer. Cancer 48 1684-1687.
57. Williams G, Anderson E, Howell A, Watson R, Coyne J, Roberts SA & Potten CS 1991 Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. International Journal of Cancer 48 206-210.
58. Williams DB, Voigt BJ, Fu YS, Schoenfeld MJ & Judd HL 1994 Assessment of less than monthly progestin therapy in post-menopausal women given estrogen replacement. Obstetrics and Gynecology 84 787-793.